Incyte stock holds near its yearly high as RBC keeps target

Published on 09/23/2026 at 13:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Incyte stock closed at USD 124.65 on September 22, 2026, while RBC kept its USD 109 target. July revenue rose 37.7 percent to USD 1.67 billion.

Fotorealistisches Biopharma-Labor mit Wissenschaftlern und bunten Zellkulturen — Incyte Biopharma-Forschungslabor zeigt Wissenschaftler an Mikroskopen, Petrischalen und Zentrifugen, ISIN US45337C1027 Biotech, Illustration mit AI erstellt.

Incyte Corporation (ISIN US45337C1027) closed at USD 124.65 on Nasdaq on September 22, 2026, only USD 7.95 below its 52-week high of USD 132.60. The company also has a near-term data event: according to Incyte on September 22, 2026, data from its inflammation and autoimmunity portfolio will be presented at the EADV Congress from September 30 through October 3, 2026, in Vienna.

RBC target stays below the quote

Royal Bank of Canada reissued a Sector Perform rating and kept its USD 109.00 price target on September 22, 2026, according to MarketBeat. The target was USD 15.65 below the September 22 closing price, a difference of 12.6 percent, while the same report cited a Moderate Buy consensus and an average target of USD 124.05.

The valuation contrast is therefore concrete: RBC's target sits below the market quote, whereas the reported average target was USD 0.60 below the close. Incyte opened at USD 125.33 on September 22, 2026, and its market capitalization was about USD 25.40 billion.

July quarter delivered a clear beat

Incyte's latest reported quarter ended in July 2026 and was released on July 28, 2026. According to MarketBeat, revenue reached USD 1.67 billion, up 37.7 percent from the year-earlier quarter and above the USD 1.50 billion analyst estimate.

Quarterly EPS was USD 3.09, exceeding the USD 2.15 consensus by USD 0.94 and rising from USD 1.57 in the comparable prior-year period. The July 2026 report also showed a net margin of 27.71 percent, giving the earnings result a measurable counterweight to the cautious RBC valuation.

Data presentations set the next checkpoint

The EADV program covers Incyte's inflammation and autoimmunity portfolio, including presentations involving hidradenitis suppurativa, atopic dermatitis and prurigo nodularis, according to Investing.com on September 22, 2026. For the stock, the scheduled September 30 to October 3, 2026 window links the current valuation to a dated clinical-data catalyst.

Stock remains below the 52-week high

Incyte stock closed at USD 124.65 on Nasdaq on September 22, 2026. The 52-week range was USD 81.09 to USD 132.60, and the market capitalization stood at USD 25.40 billion as of the same date.